FDA warned Amazon that three creams sold and shipped through Fulfillment by Amazon are unapproved new drugs for phimosis and balanitis.
What happened
In May 2026, FDA bought three products on www.amazon.com — "Vajraang Phimosis Mini Combo," "Penile Heal Cream" and "Beilloso Balanitis Relief Cream" — and reviewed their labeling. FDA says Amazon shipped each one directly to individual U.S. consumers on behalf of third parties through its Fulfillment by Amazon service. The labels claim to treat phimosis, paraphimosis and balanitis, which makes the products drugs, and FDA found no approved application for any of them.
What FDA found
The labels say the creams treat phimosis, paraphimosis and balanitis, so they are drugs under the law.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)The creams are not generally recognized as safe and effective for what their labels say, so they count as new drugs.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)No FDA-approved application is in effect for these products, so selling them across state lines is illegal.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)The Beilloso cream claims relief from balanitis, which goes beyond the allowed over-the-counter antifungal claims and does not fit any FDA final order.
Section 505G of the FD&C Act
What FDA wants
FDA tells Amazon to find the root causes, put corrective and preventive measures in place, and send a written response with the steps taken and supporting documents. The response is due within 15 business days of receiving the letter, marked with reference number 728814.
Who should pay attention
- online marketplaces that store, pack and ship third-party health products
- sellers of creams making claims about phimosis or balanitis
- brands relying on marketplace fulfillment for drug-labeled items
This is a summary. Read the original letter on fda.gov.